Fulestra 250 mg PFS Injection 5 ml

Fulestra 250 mg PFS Injection 5 ml belongs to the class of estrogen blockers used to treat breast cancer in postmenopausal women. Breast cancer is a type of cancer that develops when the breast cells begin to grow abnormally.

Fulestra 250 mg PFS Injection 5 ml contains Fulvestrant, which works by inhibiting some of the actions of estrogen (female sex hormone which may help cancer cells grow in women with breast cancer) and reducing the amount that is in the body. Thus, it helps in reducing breast cancer tumour growth.

Fulestra 250 mg PFS Injection 5 ml will be administered by a healthcare professional; do not self-administer. In some cases, Fulestra 250 mg PFS Injection 5 ml may cause certain common side effects such as injection site reactions like pain and/or inflammation, weakness, nausea, tiredness, headache or joint and musculoskeletal pain. Most of these side effects of Fulestra 250 mg PFS Injection 5 ml do not require medical attention and gradually resolve over time. However, if these side effects persist or worsen, please consult your doctor.

If you are allergic to Fulvestrant or any other medicines, please tell your doctor. Fulestra 250 mg PFS Injection 5 ml is not recommended for pregnant women as it may harm an unborn baby. Fulestra 250 mg PFS Injection 5 ml is contraindicated for use during lactation. Avoid alcohol consumption while receiving Fulestra 250 mg PFS Injection 5 ml. Avoid driving or operating machinery if you feel tired or weak after receiving Fulestra 250 mg PFS Injection 5 ml.

Fulestra 250 mg PFS Injection 5 ml is used in the treatment of Breast cancer in postmenopausal women. The detailed uses of Fulestra 250 mg PFS Injection 5 ml are as follows:

• Treatment of breast cancer: Fulestra 250 mg PFS Injection 5 ml is used in the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer in postmenopausal women.
• Treatment of progressed cancer: Fulestra 250 mg PFS Injection 5 ml is prescribed when the cancer has progressed following prior endocrine therapy.

• Your doctor will decide the dosage and timing of Fulestra 250 mg PFS Injection 5 ml based on the stage of cancer and your body’s response to the treatment. Usually, it is given every two weeks for the first three doses, then once monthly.
• Fulestra 250 mg PFS Injection 5 ml will be administered by a doctor or nurse in a medical facility.
• Do not self-administer.

Fulestra 250 mg PFS Injection 5 ml contains Fulvestrant, used to treat breast cancer in postmenopausal women. Additionally, Fulestra 250 mg PFS Injection 5 ml may be used in combination with palbociclib to treat women with a type of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that is locally advanced or has spread to other parts of the body (metastatic).

If you are allergic to Fulvestrant or any other medicines, please tell your doctor. Fulestra 250 mg PFS Injection 5 ml is not recommended for pregnant women as it may harm an unborn baby. Using effective contraception while being treated with Fulestra 250 mg PFS Injection 5 ml and for two years after the last dose is advised. Fulestra 250 mg PFS Injection 5 ml is contraindicated for use during lactation. Avoid alcohol consumption while receiving Fulestra 250 mg PFS Injection 5 ml. Avoid driving or operating machinery if you feel tired or weak after receiving Fulestra 250 mg PFS Injection 5 ml.